CRNN over-expression promotes the growth of cSCC xenografts in vivo. by Changji Li (4806930)

Subjects:

Absolute and relative cardiomyopathy and myocarditis DALYs rate attributable to 2^nd level risk factors in Chile. by Camilo Briones-Valdivieso (21567535)

Subjects:

Absolute and relative ischaemic heart disease DALYs rate attributable to 2^nd level risk factors in Chile. by Camilo Briones-Valdivieso (21567535)

Subjects:

Absolute and relative stroke DALYs rate attributable to 2^nd level risk factors in Chile. by Camilo Briones-Valdivieso (21567535)

Subjects:

Absolute and relative overall CVD DALYs rate attributable to 2^nd-level risk factors in Chile. by Camilo Briones-Valdivieso (21567535)

Subjects:

Absolute and relative atrial fibrillation and flutter DALYs rate attributable to 2^nd level risk factors in Chile. by Camilo Briones-Valdivieso (21567535)

Subjects:

Absolute and relative hypertensive heart disease DALYs rate attributable to 2^nd level risk factors in Chile. by Camilo Briones-Valdivieso (21567535)

Subjects:

Absolute and relative aortic aneurysm DALYs rate attributable to 2^nd level risk factors in Chile. by Camilo Briones-Valdivieso (21567535)

Subjects:

Absolute and relative overall CVD DALYs rate attributable to 1^st-level risk factors in Chile. by Camilo Briones-Valdivieso (21567535)

Subjects:

Absolute and relative lower extremity peripheral arterial disease DALYs rate attributable to 2^nd level risk factors in Chile. by Camilo Briones-Valdivieso (21567535)

Subjects:

S8 File - by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Study populations of included studies. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Future research directions. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

PRISMA flow diagram. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

S9 File - by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

S7 File - by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

Participant characteristics of included studies. by Martha R. Smith (20410184)

“…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”

The sequences of si-RNAs used in this study. by Changji Li (4806930)

Subjects:

Line graph illustrating mean random blood glucose (mmol/L) at weekly intervals during the induction phase. by Elsie D. Oduor (22521785)

Mean lesion depth of the SDF test groups and the SDF-free group at baseline and post-cycling time points. by Suphanida Kaewkamchai (19762172)